Amneal Pharmaceuticals’ Q4 sales rose 18% to $730.52M, surpassing estimates, while adjusted EPS missed. The company forecasts up to $3.1B in 2025 revenue.
Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars
